Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma.
Chemoradiotherapy
Hypoxia
MOLLI T1-Mapping
MRI
Oxygen Enhanced MRI (OE-MRI)
Tumour
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
17
02
2020
accepted:
01
03
2020
entrez:
27
3
2020
pubmed:
27
3
2020
medline:
27
3
2020
Statut:
epublish
Résumé
Oxygen-enhanced magnetic resonance imaging (MRI) and T1-mapping was used to explore its effectiveness as a prognostic imaging biomarker for chemoradiotherapy outcome in anal squamous cell carcinoma. T2-weighted, T1 mapping, and oxygen-enhanced T1 maps were acquired before and after 8-10 fractions of chemoradiotherapy and examined whether the oxygen-enhanced MRI response relates to clinical outcome. Patient response to treatment was assessed 3 months following completion of chemoradiotherapy. A mean T1 was extracted from manually segmented tumour regions of interest and a paired two-tailed There was a significant increase in T1 of the tumour ROIs across patients following the 8-10 fractions of chemoradiotherapy (paired These clinical data demonstrate feasibility and potential for T1-mapping and oxygen enhanced T1-mapping to indicate perfusion or treatment response in tumours of this nature. These data show promise for future work with a larger cohort containing more non-responders, which would allow us to relate these measurements to clinical outcome.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Oxygen-enhanced magnetic resonance imaging (MRI) and T1-mapping was used to explore its effectiveness as a prognostic imaging biomarker for chemoradiotherapy outcome in anal squamous cell carcinoma.
MATERIALS AND METHODS
METHODS
T2-weighted, T1 mapping, and oxygen-enhanced T1 maps were acquired before and after 8-10 fractions of chemoradiotherapy and examined whether the oxygen-enhanced MRI response relates to clinical outcome. Patient response to treatment was assessed 3 months following completion of chemoradiotherapy. A mean T1 was extracted from manually segmented tumour regions of interest and a paired two-tailed
RESULTS
RESULTS
There was a significant increase in T1 of the tumour ROIs across patients following the 8-10 fractions of chemoradiotherapy (paired
CONCLUSIONS
CONCLUSIONS
These clinical data demonstrate feasibility and potential for T1-mapping and oxygen enhanced T1-mapping to indicate perfusion or treatment response in tumours of this nature. These data show promise for future work with a larger cohort containing more non-responders, which would allow us to relate these measurements to clinical outcome.
Identifiants
pubmed: 32211520
doi: 10.1016/j.ctro.2020.03.001
pii: S2405-6308(20)30014-8
pmc: PMC7082428
doi:
Types de publication
Journal Article
Langues
eng
Pagination
44-49Subventions
Organisme : Medical Research Council
ID : MC_PC_12001/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00001/2
Pays : United Kingdom
Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Cancer Res. 2016 Feb 15;76(4):787-95
pubmed: 26659574
Ann Oncol. 2014 Sep;25 Suppl 3:iii10-20
pubmed: 25001200
Magn Reson Med. 2016 Jun;75(6):2442-7
pubmed: 26175346
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):552-8
pubmed: 22019078
Magn Reson Med. 2007 Sep;58(3):490-6
pubmed: 17763345
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S101-7
pubmed: 20171503
Magn Reson Med. 2014 May;71(5):1863-73
pubmed: 23813468
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800
pubmed: 17379452
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S130-4
pubmed: 20171507
Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):587-94
pubmed: 25194664
Magn Reson Med. 2006 Aug;56(2):240-6
pubmed: 16795082
Radiother Oncol. 2016 Aug;120(2):228-33
pubmed: 27406441
Lancet Oncol. 2013 May;14(6):516-24
pubmed: 23578724
Br J Radiol. 2019 Mar;92(1095):20180642
pubmed: 30272998
Cancer. 1999 Apr 15;85(8):1686-93
pubmed: 10223561
Magn Reson Med. 2008 Dec;60(6):1313-20
pubmed: 19030165
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1064-72
pubmed: 20350793
Clin Oncol (R Coll Radiol). 2014 Nov;26(11):720-1
pubmed: 25183394
Magn Reson Med. 2006 Mar;55(3):566-74
pubmed: 16450365
Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1209-15
pubmed: 19327904
Magn Reson Imaging. 1997;15(1):123-6
pubmed: 9084033
NMR Biomed. 2015 Aug;28(8):937-947
pubmed: 26058575
Clin Oncol (R Coll Radiol). 2016 Sep;28(9):604-10
pubmed: 27156162
J Magn Reson Imaging. 1997 Jan-Feb;7(1):220-5
pubmed: 9039619
Clin Oncol (R Coll Radiol). 2018 Oct;30(10):634-641
pubmed: 30049649
Magn Reson Imaging. 1987;5(3):201-8
pubmed: 3626789
J Clin Oncol. 2012 Dec 10;30(35):4344-51
pubmed: 23150707
Magn Reson Med. 2004 Jul;52(1):141-6
pubmed: 15236377
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S123-9
pubmed: 20171506